KRTL Holding Announces Acquisition of Neurogen Brain Balancing

KRTL Holding Group Inc., a prominent player in biotech innovation and strategic investment, has announced the acquisition of Neurogen Brain Balancing, LLC. Based in California, Neurogen is known for its neurotechnology that supports cognitive optimization and mental wellness. This acquisition marks a strategic expansion of KRTL's portfolio in mental health solutions. Neurogen will become a subsidiary of KRTL, and its proprietary neuromodulation technology will integrate into KRTL's ecosystem, ensuring global scalability. Through this merger, KRTL plans to enhance Neurogen’s market entry, regulatory services, and overall growth while maintaining a focus on non-opioid, non-invasive treatment solutions. The acquisition structure includes a stock-based deal with profit-sharing and regulatory alignment for new market expansions. KRTL's integration efforts focus on operational and regulatory alignment, supported by internal and third-party advisors. Strategic growth will be informed by their Quality Management System (QMS) and Enterprise Resource Planning (ERP) for improved long-term performance. Further developments will be shared through forthcoming announcements.